December 8, 2017
Sanofi and Asahi Kasei Pharma enter license agreement for marketing of Kevzara® Subcutaneous Injection, a treatment for rheumatoid arthritis, in Japan
November 30, 2017
Maruho and Asahi Kasei Pharma Announce Phase 3 Clinical Study Results of Famciclovir for the Treatment of Recurrent Herpes Simplex
October 20, 2017
Asahi Kasei Pharma received 510(k) clearance from the FDA for Lucica® Glycated Albumin-L
June 5, 2017
Application for import drug registration for Flivas™ (naftopidil) in China
May 18, 2017
Asahi Kasei Pharma receives approval to extend treatment duration for Teribone™ osteoporosis drug
January 12, 2017
Announcement of marketing of Bredinin™ OD25 and Bredinin™ OD50
November 18, 2016
Announcement of listing on the NHI drug price standard and marketing of Reclast®
September 28, 2016
Approval for manufacture and sale of Reclast® in Japan
September 15, 2016
License agreement for new antifungal agent
August 5, 2016
Completion of a new pharmaceutical manufacturing facility in Fuji
July 22, 2016
Application to extend duration of treatment for Teribone™ osteoporosis drug
June 22, 2016
Global strategic collaboration with Orion Corporation
April 1, 2016
License agreement for chronic pain drug
April 1, 2016
Launch of Teribone™ osteoporosis drug in Korea
March 28, 2016
Joint R&D with PeptiDream Inc.
March 17, 2016
Discontinuation of joint sales of NEOXY® Tape 73.5 mg transdermal overactive bladder treatment medication
February 15, 2016
Termination of co-promotion agreement on Recomodulin™ anticoagulant intravenous infusion 12800
November 18, 2015
Approval for sale of Teribone™ in Korea
September 30, 2015
Application for approval to manufacture and market zoledronic acid hydrate for treatment of Osteoporosis in Japan
August 31, 2015
Announcement of listing on the NHI drug price standard and marketing of XIAFLEX® (collagenase clostridium histolyticum)
Page Top